Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Innate Pharma (OTC: IPHYF).

Full DD Report for IPHYF

You must become a subscriber to view this report.


Recent News from (OTC: IPHYF)

AstraZeneca to acquire 9.8% of Innate Pharma
Reuters reports that AstraZeneca (NYSE: AZN ) will acquire a 9.8% stake in French outfit Innate Pharma ( OTCPK:IPHYF ) via the purchase of ~6.26M newly issued shares at 10 euros per share. More news on: AstraZeneca Group plc, Innate Pharma, Healthcare stocks news, Merger & acquisitio...
Source: SeekingAlpha
Date: October, 23 2018 07:30
Innate Pharma SA (IPHYF) CEO Mondher Mahjoubi on H1 2018 Results - Earnings Call Transcript
Innate Pharma SA (IPHYF) H1 2018 Results Conference Call September 14, 2018 08:00 ET Executives Mondher Mahjoubi - CEO Laure-Helene Mercier - CFO Pierre Dodion - CMO Analysts Jonathan Chang - Leerink Partners Presentation Operator Good afternoon ladies and gentlem...
Source: SeekingAlpha
Date: September, 14 2018 14:47
Innate Pharma reports FY results
Innate Pharma ( OTCPK:IPHYF ): FY EPS of -€0.89 More news on: Innate Pharma, Innate Pharma ADR, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: March, 08 2018 05:46
Innate Pharma's (IPHYF) CEO Mondher Mahjoubi on Q2 2017 Results - Earnings Call Transcript
Innate Pharma (IPHYF) Q2 2017 Earnings Conference Call September 18, 2017 09:00 AM ET Executives Mondher Mahjoubi - CEO Laure-Helene Mercier - CFO Pierre Dodion - CMO Yannis Morel - EVP, Product Portfolio Strategy and Business Development Analysts Michael Schmidt - Leerin...
Source: SeekingAlpha
Date: September, 18 2017 14:46

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-148.638.638.638.63175
2018-12-13N/A9.00N/AN/A0
2018-12-12N/A9.00N/AN/A0
2018-12-11N/A9.00N/AN/A94
2018-12-109.009.009.009.00300

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-10300300100.0000Short
2018-12-0620068329.2826Cover
2018-12-035021523.2558Cover
2018-11-3050061880.9061Short
2018-11-29100100100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IPHYF.


About Innate Pharma (OTC: IPHYF)

Logo for Innate Pharma (OTC: IPHYF)

Innate Pharma specializes in immuno oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body s own immune cells to recognize and kill cancer cells. The Company has pioneered the development of antibodies that block inhibitory checkpoint receptors on NK cells. Today, Innate Pharma has three first in class antibodies in clinical development in immuno oncology and a pipeline of preclinical candidates to novel targets and mechanisms. Its innovative approach has translated into alliances with leaders in the biopharmaceutical industry such as AstraZeneca, Bristol Myers Squibb, Novo Nordisk A/S and Sanofi. Based in Marseille, France, Innate Pharma had employees as at March , . The company is listed on Euronext Paris.

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $263,099,505 - 03/16/2018
  • Issue and Outstanding: 38,135,890 - 01/16/2014

 



Daily Technical Chart for (OTC: IPHYF)

Daily Technical Chart for (OTC: IPHYF)


Stay tuned for daily updates and more on (OTC: IPHYF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: IPHYF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IPHYF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of IPHYF and does not buy, sell, or trade any shares of IPHYF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/